- Reagents
- Peptide Synthesizers
- Chromatography equipment
Refurbished Peptide Synthesizers Market size is valued at USD 512 million in 2021 and is expected to reach USD 705 million by 2028, at a CAGR of 7.1% during the forecast period 2022-2028. Peptide-based medications are classified as small-molecule biologic or large-molecule biologics. Peptides, which fall in between small molecules and large proteins, have created a slew of regulatory issues. Chemically produced pharmaceuticals make up the majority of these medications. Despite the fact that the production method for several peptide medicines is similar, their action mechanisms differ significantly. As a result, creating an uniform set of regulatory rules that can effectively meet the safety and quality criteria for such a broad range of molecular entities with diverse modes of action is a difficult undertaking. There are no established guidelines for developing this class of medications from any regulatory agency. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are also at odds over the regulatory approval of peptide-based medications. According to the FDA, peptide medications are classified as small-molecule pharmaceuticals and fall under the jurisdiction of the FDA's Center for Drug Evaluation and Research (CDER); nevertheless, the EMA favors a centralized system over mutual recognition (the marketing of peptide-based drugs is allowed throughout the European Union under the centralized procedure). Due to the lack of a consistent set of rules, obtaining permits for therapeutic peptides has proven difficult, limiting their application areas. This is seen as a major stumbling block to the global peptide synthesis market's expansion. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Global Refurbished Peptide Synthesizers Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Global Refurbished Peptide Synthesizers Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Peptides are pharmacological compounds that are both highly active and very selective. They are employed in a wide range of therapeutic areas due to the diversity of their biological actions. Because of their broad chemical space, high biological activity, high specificity, relative simplicity of synthesis, accessible availability, and low toxicity, peptides are increasingly being considered as potential active pharmacological components in medication development. Peptides contribute billions of dollars in income in three major therapeutic areas: oncology, diabetes, and obesity. The use of peptides in the treatment of cardiovascular and neurological illnesses, renal failure, and uncommon diseases is also on the rise. There are over 100 FDA-approved peptide-based medications on the market right now.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.